지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2010.1
- 수록면
- 530 - 536 (7page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Adefovir (ADV) is the preferred drug for treating lamivudine (LAM)-resistant hepatitis B. However, not all patients who face virologic breakthrough during LAM treatment respond to ADV. The aim of this study was to determine the factors associated with efficacy of ADV in LAM-resistant hepatitis B patients. Methods: The medical records of 231 patients who received ADV due to LAM-resistance were reviewed. Efficacy was assessed by the initial virologic response (IVR), defined as hepatitis B virus (HBV) DNA not being undetectable by real-time PCR at 6 months of ADV treatment. Results: Seventy patients (30%) achieved IVR. While ‘add-on’ modality,hepatitis B e antigen (HBeAg) negativity, and low baseline HBV DNA levels were associated with IVR in univariate analysis, multivariate analysis revealed HBeAg status and the DNA level to be the significant factors.
The probability of IVR achievement increased sharply per each log10 copies/mL decrement in the baseline viral load, which was 133 times in patients who had HBV DNA ＜105 copies/mL compared with those who had ≥108 copies/mL. Conclusions: Factors associated with the IVR were HBeAg negativity and a low baseline viral load. Therefore, when virologic breakthrough with genotypic resistance emerges during LAM therapy, ADV treatment should be considered immediately before further increases in viral load.
Additional long-term follow-up data are warranted
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Asahina Y / 2003 / Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C / J Hepatol 39 : 1063 ~ 1069
Chang ML / 2005 / Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B / J Hepatol 43 : 72 ~ 7
Chen CH / 2006 / Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil / Antivir Ther 11 : 771 ~ 778
European Association for the Study of the Liver / 2009 / EASL Clinical Practice Guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
Fung SK / 20
Chang ML / 2005 / Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B / J Hepatol 43 : 72 ~ 7
Chen CH / 2006 / Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil / Antivir Ther 11 : 771 ~ 778
European Association for the Study of the Liver / 2009 / EASL Clinical Practice Guidelines: management of chronic hepatitis B / J Hepatol 50 : 227 ~ 242
Fung SK / 20
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
만성 B형간질환 환자의 라미부딘 내성 예측인자
Clinical and Molecular Hepatology
2007 .01
-
만성 B형간염 환자에 대한 초치료제로서 엔테카비어의 항바이러스 효과와 그 예측인자
Clinical and Molecular Hepatology
2010 .01
-
만성 B형간염에서 라미부딘 치료에 의한 혈청 HBV DNA치의 변화와 Viral Breakthrough의 관련성
Clinical and Molecular Hepatology
2006 .01
-
만성 B형 간질환에서 라미부딘 내성의 임상경과 및 예측인자
Clinical and Molecular Hepatology
2003 .01
-
라미부딘 투약 후 혈청 HBeAg 소실의 인자로서 투약 후 HBV DNA치
Clinical and Molecular Hepatology
2007 .01
-
Virologic Response at 12 Months of Treatment Predicts Sustained Antiviral Efficacy in Patients with Adefovir-Treated Lamivudine-Resistant Chronic Hepatitis B
Gut and Liver
2010 .01
-
Factors Predicting the Effi cacy of Adefovir Dipivoxil on Treatment-Naïve Chronic Hepatitis B Patients at 48 Weeks
Gut and Liver
2011 .01
-
만성 바이러스성 B형 간염 환자에서 HBeAg이 혈청전환된 1례
대한한방내과학회지
2016 .01
-
라미부딘 내성이 발생한 만성 B형간염에서 아데포비어에 대한 초기 치료 반응이 아데포비어 내성 발생에 미치는 영향
Clinical and Molecular Hepatology
2007 .01
-
Lamivudine Therapy for Korean Children with Chronic Hepatitis B
Yonsei Medical Journal
2007 .01
-
라미부딘 내성 만성 B형간염 환자에서 아데포비어 투여에 따른 내성 바이러스 출현 및 초기 바이러스반응에 미치는 인자
Clinical and Molecular Hepatology
2008 .01
-
만성 B형 바이러스성 간염환자에서 lamivudine 52주 투여의 치료효과에 대한 연구
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
2001 .01
-
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
Clinical and Molecular Hepatology
2011 .01
-
아데포비어 단독요법에 반응을 보인 라미부딘 내성 HBeAg 양성 만성 B형간염 환자에서 아데포비어 중단 후 임상경과
Clinical and Molecular Hepatology
2009 .01
-
만성 B형 간염 환자의 추적 관찰시 효소면역법을 이용한 HBeAg 정량검사의 유용성
Annals of Laboratory Medicine
2002 .01
-
HBeAg 음성 만성 B형 간질환에서 Lamivudine의 치료 효과
Clinical and Molecular Hepatology
2003 .01
-
Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B
Laboratory Medicine Online
2019 .01
-
만성 B형 간질환에서 라미부딘 초치료 후의 재발 양상과 재치료 효과
Clinical and Molecular Hepatology
2003 .01
-
약제 내성 만성 B형 간염 환자에서 S202, M250 엔테카비어 내성이테노포비어 근간 구제 요법의 바이러스 반응에 미치는 영향
대한내과학회지
2015 .01
-
소아 만성 B형 간염의 관리와 치료
Clinical and Experimental Pediatrics
2007 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0